Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Buy” at Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Sunday.

SUPN has been the topic of several other research reports. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $53.87 on Friday. The firm has a market capitalization of $3.10 billion, a P/E ratio of -79.22, a PEG ratio of 1.67 and a beta of 0.70. Supernus Pharmaceuticals has a one year low of $29.16 and a one year high of $59.68. The company’s 50-day simple moving average is $50.99 and its 200 day simple moving average is $48.78.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 710 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the sale, the vice president directly owned 14,508 shares in the company, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $781,153.36. The trade was a 56.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 25,185 shares of company stock valued at $1,268,022 over the last 90 days. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Supernus Pharmaceuticals by 8.8% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after acquiring an additional 1,161 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Supernus Pharmaceuticals by 30.4% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after acquiring an additional 19,949 shares during the period. Ruffer LLP purchased a new position in shares of Supernus Pharmaceuticals during the third quarter valued at approximately $2,647,000. Systematic Financial Management LP raised its holdings in shares of Supernus Pharmaceuticals by 47.5% during the second quarter. Systematic Financial Management LP now owns 245,545 shares of the specialty pharmaceutical company’s stock valued at $7,740,000 after purchasing an additional 79,041 shares during the last quarter. Finally, Villanova Investment Management Co LLC lifted its position in Supernus Pharmaceuticals by 167.1% during the second quarter. Villanova Investment Management Co LLC now owns 52,324 shares of the specialty pharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 32,737 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.